
Monday, September 16, 2024 2:51:31 PM
NEW OPPORTUNITIES/MARKETS/PRODUCTS
Several new collaborations in developing products for wound care, cancer treatment, and an antipathogenic coating for catheters.
All three markets mentioned here from Jan presentation are markets that Solventum sells products in.
I bring up Solventum because Zimmer Biomets former CEO Bryan Hanson is now CEO of Solventum and knows all about Sintx IP from his Zimmer days
Bryan Hanson & 3M's Solventum
wound care, oral care, health care IT, and biopharma filtration
Quote Source:
https://d1io3yog0oux5.cloudfront.net/_9be13c70ea13288f968a56d0f02f5862/sintx/db/443/4298/pdf/SINTX+Corporate+Overview+-+Jan+%2724+-+Rev+J.pdf
https://news.3m.com/2023-08-22-Bryan-Hanson-Named-CEO-of-3Ms-Health-Care-Business-Group
https://www.3m.com/3M/en_US/medical-us/solutions/catheter-movement/
========================================
Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
========================================
Section 3 - PioneerPhoenix73 has some misinformation in its post, purposeful or not. Some factual corrections needed in its post:
1. Zimmer Biomet did not acquire Implex as Zimmer Biomet did not exist in 2003. Zimmer acquired Implex 12 years before Zimmer became Zimmer Biomet.
2. Implex material was porous version of tantalum metal it called Hydrocel and Zimmer calls Trabecular Metal. Completely different material and a metal not ceramic.
3. Sintx tech is heavily patented making it very difficult for a partner company to steal its tech. As well as any partnership agreement would likely have extra clauses to prevent such a scenario. The scenario is highly unlikely in Western countries.
4. Sintx is the only company with medical grade Si3n4 with over 100 patents pending worldwide making it unlikely that Zimmer Biomet could license the tech from any other company. Furthermore testing of products related to Sintx and Biomet IP were tested in 2016, & 2018 showing further collaberation well after that 2011 quote. Zimmer Biomet even hired a Si3N4 coatings expert end of 2018 showing continued interest past 2018. Large companies like Zimmer Biomet use small companies like Sintx to de-risk IP and then acquire it. Thats exactly how J&J operates. Does that guarantee anything? No it does not. However according to one scientist, Silicon Nitride is destined to replace current materials used in many fields of medicine.
These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology.
In Figure 1, you can see J&J makes most of its money from pharmaceuticals and medical devices. They have grown these two sectors over the past decade through major capital investments in acquisitions and people development. Instead of investing in developing technology in-house, they use their size to acquire smaller companies who they believe have a promising trajectory in the healthcare space.
We believe we are the only FDA-registered and ISO 13485:2016 certified silicon nitride medical device manufacturing facility in the world, and the only provider of structural ceramics-based medical devices used for spinal fusion applications
Quote Sources:
https://web.archive.org/web/20240408152758/https://sintx.com/wp-content/uploads/2021/03/Investor-Call-Transcript-033021.pdf
https://d3.harvard.edu/platform-rctom/submission/a-family-of-companies-johnson-johnson/
https://www.sec.gov/ix?doc=/Archives/edgar/data/1269026/000149315224011546/form10-k.htm pg 7
Could it be that there is a strategy to distract people away from looking at the basic data?
Is all this an exercise to create more and more forum verbiage to drown out any serious discussion of evidence?
Recent SINT News
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/14/2025 10:08:19 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/14/2025 09:42:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2024 09:15:30 PM
- SINTX Technologies Secures Patent Allowance for Wide-Ranging Silicon Nitride Biomaterial Applications • GlobeNewswire Inc. • 12/17/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2024 09:15:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2024 06:15:19 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/26/2024 11:10:12 AM
- SINTX Technologies and NED Medical Partner to Advance Cutting-Edge Ceramic Microsphere Medical Devices for Cancer Treatment • GlobeNewswire Inc. • 11/21/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/19/2024 10:13:22 PM
- SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer • GlobeNewswire Inc. • 11/19/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/18/2024 11:15:16 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/15/2024 12:25:52 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/14/2024 09:15:08 PM
- SINTX Technologies Provides Positive Strategic Business Update for Q3 2024 • GlobeNewswire Inc. • 11/14/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 08:50:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 08:30:16 PM
- SINTX Announces Key Executive Promotions: Ryan Bock, PhD, Named Chief Technology Officer and Ann Kutsch Promoted to President of SINTX TA&T • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2024 08:30:31 PM
- Prodways and SINTX Announce Joint Webinar Stay Ahead of the Curve: “Innovations in Ceramic Manufacturing: The Role of 3D Printing” • GlobeNewswire Inc. • 09/20/2024 12:00:00 PM
- SINTX Announces Completion of $3.1 Million ATM Equity Public Offering • GlobeNewswire Inc. • 09/19/2024 12:00:00 PM
- Apple Loses EU Dispute; Google’s $2.7 Billion Fine Upheld; Oracle Shares Surge 9% • IH Market News • 09/10/2024 10:02:31 AM
- SINTX Receives Notice of Allowance for United States Patent Application for Silicon Nitride-Functionalized Zirconia-Toughened Alumina Ceramic Biomaterial • GlobeNewswire Inc. • 09/09/2024 12:00:00 PM
- Significant Cost Reductions, Extended Cash Runway, and Exploration of Strategic Partnerships • GlobeNewswire Inc. • 09/05/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:32:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 01:05:17 PM
COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups • COEP • Feb 13, 2025 9:10 AM
Unitronix Corp. to Report Over 300% Gains in Cryptocurrency Assets • UTRX • Feb 13, 2025 7:15 AM
Hivello Token ($HVLO) now Live • MATE • Feb 11, 2025 9:27 AM
Animoca Brands leads Hivello funding round ahead of Token Listing • MATEF • Feb 10, 2025 10:20 AM
51 Labs Expands Sports Nutrition Line with Five New Innovative Products, Company in final phase of name and ticker symbol change • CAFI • Feb 10, 2025 9:00 AM
UAV Corp. Expanding in the Global UAV Market, Projected to Exceed $58 Billion by 2027, with Increasing Government and Commercial Sector Adoption • UMAV • Feb 6, 2025 8:30 AM